Document Detail


Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men?
MedLine Citation:
PMID:  21084399     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Short-term testosterone (T) treatment in frail elderly men improves muscle mass and strength. It is unclear whether these effects can be maintained post treatment.
OBJECTIVE: To assess the durability of androgen effects in frail men.
DESIGN AND SETTING: Single center, randomized, double-blind, placebo-controlled trial to investigate the effects of 6 months T (25-75 mg daily) on muscle strength, body composition, physical function, and quality of life (QoL). Participants were assessed at the end of treatment (6 months) and 6 months after treatment cessation (12 months).
PARTICIPANTS: 274 intermediate-frail and frail elderly men aged 65-90 years with low T levels.
RESULTS: Mean T increased from 11.1 (3.1) nmol/liter at baseline to 18.4 (3.5) nmol/liter at 6 months, then declined to 10.5 (3.7) nmol/L at 12 months, in the T-treated group. Isometric knee extension peak torque increased in the T-treated group compared with placebo to give an adjusted mean difference (95% CI) between groups of 8.1 (-0.2 to 16.5) Nm at 6 months. Lean mass increased in the T-treated group giving a difference between groups of 1.2 (0.8 to 1.7) kg at 6 months. Somatic and sexual symptoms improved during treatment. None of these differences between groups remained at 12 months. Prostate specific antigen (PSA) levels and haematocrit increased slightly during treatment but returned to baseline by 12 months.
CONCLUSION: The effects of 6-month T treatment on muscle strength, lean mass, and QoL in frail men are not maintained at 6 months post treatment.
Authors:
Matthew D L O'Connell; Stephen A Roberts; Upendram Srinivas-Shankar; Abdelouahid Tajar; Martin J Connolly; Judith E Adams; Jackie A Oldham; Frederick C W Wu
Related Documents :
12700569 - The effect of total shoulder arthroplasty on self-assessed health status is comparable ...
20150039 - Quality of life after 114 months of follow-up following geometric reconstruction of the...
17627239 - Quality of life after randomization to laparoscopic versus open living donor nephrectom...
11460909 - Tumour surgery of the upper cervical spine--a retrospective study of 13 cases.
23397879 - The effectiveness of digital microscopy as a teaching tool in medical laboratory scienc...
25043889 - Defining utility and predicting outcome of cadaveric lower extremity bypass grafts in p...
10714019 - Clinical experience of argatroban for anticoagulation in cardiovascular surgery.
2597599 - Effects of benfluorex in obese patients with metabolic disorders.
19916729 - Retrospective study of total healthcare costs associated with chronic nonvalvular atria...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-11-17
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  96     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-07     Completed Date:  2011-03-21     Revised Date:  2012-02-16    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  454-8     Citation Subset:  AIM; IM    
Affiliation:
Andrology Research Unit, Manchester Academic Health Science Centre, Manchester Royal Infirmary, The University of Manchester, Manchester, United Kingdom.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00190060
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorptiometry, Photon
Aged
Aged, 80 and over
Body Composition / drug effects*
Cholesterol, HDL / blood
Double-Blind Method
Frail Elderly*
Hematocrit
Humans
Isometric Contraction
Luteinizing Hormone / blood
Male
Motor Activity / drug effects*,  physiology*
Muscle Strength / drug effects*
Prostate-Specific Antigen / blood
Quality of Life*
Sex Hormone-Binding Globulin / metabolism
Sexual Behavior
Testosterone / adverse effects,  blood,  pharmacology*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Sex Hormone-Binding Globulin; 58-22-0/Testosterone; 9002-67-9/Luteinizing Hormone; EC 3.4.21.77/Prostate-Specific Antigen
Comments/Corrections
Comment In:
J Urol. 2012 Feb;187(2):622   [PMID:  22237359 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of ...
Next Document:  Wnt/{beta}-Catenin Pathway Activation in Adrenocortical Adenomas Is Frequently due to Somatic CTNNB1...